Preview

Meditsinskiy sovet = Medical Council

Advanced search

IMPORTANT FACTORS OF THE INFLAMMATORY PROCESS IN THE O ROPHARYNX AND OPTIMAL TREATMENT REGIMES SELECTION

https://doi.org/10.21518/2079-701X-2017-16-48-54

Abstract

Acute inflammatory diseases of the oropharynx dominate the medical aid appealability among all age categories. Such diseases are characterized by poly-ethiology and may form a mixed infection with bacteria and respiratory viruses. Components of bacterial cell walls, toxins, decay products of tissues during cytolysis or apoptosis of cells as a result of massive output of mature virions induce epithelial cells and macrophages for active synthesis of chemokines MCP-1, MCP-3, RANTES, IL-8, which leads to increased inflow of polymorphonuclear leukocytesin to the flammatory focus and a mass release of biogenic amines, lysosomal enzymes, cationic proteins, the release of arachidonic acid, which gradually turns into eicosanoids. Systemic use of NSAIDs can cause NSAID-associated gastropathies. Good accessibility of the target organ in diseases of the oropharynx allows target organspecific delivery of local treatment. Benzidamine hydrochloride (Tantum® Verde) refers to the group of anti-inflammatory suppressor of cytokines and also has a pronounced analgesic effect. The article provides data of the follow-up study of the efficacy of Tantum Verde® in the treatment of acute tonsillopharyngitis in outpatient settings.

About the Authors

E. L. Savlevich
Central State Medical Academy of Department of Presidential Affairs of the Russian Federation
Russian Federation

PhD in medicine.

Moscow



N. E. Doroschenko
Combined Hospital and Outpatient Clinic of Department of Presidential Affairs of the Russian Federation
Russian Federation

PhD in medicine.

Moscow



I. S. Slavinskaya
Central State Medical Academy of Department of Presidential Affairs of the Russian Federation
Russian Federation

Moscow



S. E. Farikov
Central State Medical Academy of Department of Presidential Affairs of the Russian Federation
Russian Federation

Moscow



References

1. Лопатин А.С. Лечение острого и хронического фарингита. РМЖ, 2001, 9(16): 765–769.

2. Dierig A, Heron LG, Lambert SB, Yin JK et al. Epidemiology of respiratory viral infections in children enrolled in a study of influenza vaccine effectiveness. Influenza and Other Respiratory Viruses, 2014, 8: 293-301.

3. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Van Beneden C. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2012, 55(10): 1279-82.

4. Савлевич Е.Л., Дорощенко Н.Э. Патогенетическое обоснование топической терапии воспалительной патологии ротоглотки. Фарматека, 2015, 1: 76-79.

5. Маянский А.Н., Маянский Н.А., Заславская М.И. Нуклеарный фактор-κB и воспаление. Цитокины и воспаление, 2007, 6(2): 3-9.

6. Белоцкий С.М., Авталион Р.Р. Воспаление. Мобилизация клеток и клинические эффекты. М.: Бином, 2008. 239 с.

7. Piet B, Bree GJ, Smids-Dierdorp BS, Loos CM, Remmerswaal EB, Thüsen JH. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest, 2011, 121(6): 2254–2263.

8. Зайчик А.Ш., Чурилов Л.П. Общая патофизиология с основами иммунопатологии. СПб.: ЭЛБИ-СПб, 2005. 656 с.

9. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol, 2016, 13(1): 3-10.

10. Клинические рекомендации: острый тонзиллофарингит, КР306. Министерство здравоохранения Российской Федерации, Национальная медицинская ассоциация отоларингологов, 2016 г.

11. Quane PA, Graham GG, Ziegler JB. Pharmacology of benzydamine. Inflammopharmacology. 1998, 6(2): 95-107.

12. Wethington JF. Double-blind study of benzydamine hydrochloride, a new treatment for sore throat. Clin Ther, 1985, 7(5): 641-6.

13. Nathan C et al. Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol, 2013 May, 13(5): 349–361.

14. Morgan MJ et al. TNFα and reactive oxygen species in necrotic cell death. Cell Research, 2008, 18: 343-349.

15. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 2004, 100: 2026–2046.

16. Зайцев А.А., Карпов О.И., Карпищенко С.А. Флурбипрофен: новые возможности местного лечения тонзиллофарингита. РМЖ, 2004, 17: 1003.

17. Simard-Savoie S, Forest D. Topical anaesthetic activity of benzydamine. Curr Ther Res, 1978, 23(6): 734-745.

18. Engles I. Vertraglichkeits studiemit Tantum Verde gurrgellosung. Med. Welt., 1980. 49: 3-7.

19. Scarpelli PT. Clinical study on analgesico-antiphlogistic activity of af-864 or benzidamine hydrochloride. Clin Ter, 1965 Apr 30, 33: 116-22. Адаптировано: согласно полученным клиническим данным об опыте применения препарата, опубликованным в профессиональных изданиях.


Review

For citations:


Savlevich EL, Doroschenko NE, Slavinskaya IS, Farikov SE. IMPORTANT FACTORS OF THE INFLAMMATORY PROCESS IN THE O ROPHARYNX AND OPTIMAL TREATMENT REGIMES SELECTION. Meditsinskiy sovet = Medical Council. 2017;(16):48-54. (In Russ.) https://doi.org/10.21518/2079-701X-2017-16-48-54

Views: 1073


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)